Healthcare / Diagnostics & ResearchNasdaqCM
$0.65
-0.01 (-1.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-20.7M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$33M
P/E
N/A
•EV/EBITDA
N/A
•ROE
277.2%
↑Gross Margin
64.5%
↑Debt/Equity
-7.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+42.8%
FCF CAGR
—
FCF margin
-3.1%
FCF / Net income
0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $107.9M · net income $-33.5M · FCF $-3.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $107.9M | $107.9M | $90.0M | $70.2M | $37.1M |
| Net Income | $-33.5M | $-33.5M | $-38.1M | $-43.1M | $-44.0M |
| EBITDA | $-14.6M | $-14.6M | $-22.0M | $-30.7M | $-36.5M |
| EPS | -0.67 | -0.67 | -1.16 | -1.66 | -2.80 |
| Gross Margin | 64.5% | 64.5% | 61.2% | 62.6% | 51.9% |
| Operating Margin | -14.2% | -14.2% | -26.7% | -38.1% | -103.7% |
| Net Margin | -31.1% | -31.1% | -42.3% | -61.4% | -118.9% |
| Balance Sheet | |||||
| Debt/Equity | -7.16 | -7.16 | 4.05 | 5.72 | 4.27 |
| Current Ratio | 1.63 | 1.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.3M | $-3.3M | $-20.7M | $-26.5M | $-38.3M |
| Returns | |||||
| ROE | 277.2% | 277.2% | -256.5% | -597.9% | -472.8% |
| Valuation | |||||
| P/B | — | — | 7.74 | 15.13 | 11.60 |
| Growth & Yield | |||||
| Revenue Growth | 19.8% | 19.8% | 28.3% | 89.4% | — |
| EPS Growth | 42.2% | 42.2% | 30.1% | 40.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-70.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.16 → -0.67
Residual
-70.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.